IL10 and B-cell chronic lymphocytic leukemia: Targeting IL‐10 under 3D conditions enhanced cytotoxicity and reduced exhaustion of CLL‐derived CAR T cells, particularly in the core regions, which aligns with preclinical CLL models where IL‐10 blockade reduced leukemic burden and enhanced T‐cell‐mediated antitumor responses,17, 33 as well as observations in other tumor types.32, 62, 63